Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novavax NVAX -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (31)	6/10/2009 1:01:55 PM
From: Rock_nj	Respond to of 166

What, the Swine Flu pandemic or NVAX's price? We ain't seen nothing yet on either front. A Swine Flu pandemic with no resistence in the under 60 population could easily infect 30% or 2 Billion people over the next year or so. NVAX could easily get fast track approval and be selling swine flu vaccines hand over fist by this time next year. NVAX could be a huge runner for 2009. Check this post on December 31, 2009. NVAX started about $2.80 today and is now about $3.20. Where will it be at the end of the year? I think a lot higher since they have no revenues no and might have Billions in revenues shortly.

To: tom pope who wrote (31)	6/11/2009 7:28:18 PM
From: Rock_nj	Read Replies (1) \| Respond to of 166

INTERVIEW - Novavax sees new licensing deal in Q3 - CEO Thu Jun 11, 2009 11:46pm IST * Novavax expects to ink vaccine licensing deal * In talks with cos in Europe, Asia and North America * Targeting human trials for H1N1 vaccine this year By Anand Basu BANGALORE, June 11 (Reuters) - Novavax Inc (NVAX.O: Quote, Profile, Research) expects to sign a new deal in the third quarter, with a partner outside the United States, to license its flu vaccine and possibly co-develop other infectious disease vaccines, its chief executive said. The company is also aiming to start human trials for its vaccine to treat the newly discovered H1N1 flu virus later this year, Chief Executive Rahul Singhvi said in an interview. In March, the company signed a deal with India's Cadila Pharmaceuticals Ltd (CADI.BO: Quote, Profile, Research) to commercialize Novavax's seasonal influenza vaccine candidate in India and jointly develop several other candidates for diseases such as hepatitis E and dengue fever using Novavax technology. "(The Cadila deal) was the first one that we got, but we expect we can do more of those," Chief Executive Rahul Singhvi said in an interview. "That deal is extremely helpful to us because we can get access to some very high-quality, but low-cost, infrastructure at Cadila to move forward with some of our programs," Singhvi said. Continued... in.reuters.com